Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroSense Therapeutics Ltd. filings document foreign private issuer disclosures for a clinical biotechnology company developing PrimeC for severe neurodegenerative diseases. Its Form 6-K reports cover clinical and regulatory updates, PrimeC patent protection, scientific publication of PARADIGM trial results, Nasdaq continued-listing notifications, and incorporation of selected reports into Form S-8 and Form F-3 registration statements.
The company’s regulatory record also addresses shareholder voting matters, including amendments to registered share capital, capital-structure disclosures, governance changes, material agreements, operating and financial results, and leadership or advisory arrangements tied to the PrimeC development program.
NeuroSense reported a statistically significant clinical benefit for PrimeC at 18 months. An NfL-adjusted MMRM analysis showed a p=0.03 result, corresponding to a 28% relative difference in decline on the ALS Functional Rating Scale-Revised (ALSFRS-R) favoring patients who received PrimeC from study start versus those who began with placebo and switched to PrimeC after six months. The company states these data underscore the clinical importance of initiating PrimeC early in disease progression.
NeuroSense Therapeutics Ltd. furnished a Form 6-K to provide materials for its upcoming Annual General Meeting of Shareholders scheduled for September 25, 2025. The filing attaches and incorporates a Notice and Proxy Statement for the meeting, along with a proxy card that shareholders can use to vote on the matters presented.
The company also states that this Form 6-K is incorporated by reference into several of its existing registration statements on Form S-8 and Form F-3, meaning the information in this report is now formally part of those securities offering documents.
NeuroSense Therapeutics Ltd. reports long-term follow-up data from its Phase 2a study in people with ALS treated with its drug candidate PrimeC. As of August 20, 2025, approximately 20% of people with ALS from this study, including those continuing treatment under compassionate use, remain on PrimeC for more than 5.5 years and have lived with ALS for over 7 years. Across these multi-year treatment exposures, PrimeC is described as well tolerated, with no new safety signals observed to date. The company also notes that this report is incorporated by reference into several of its existing registration statements.
NeuroSense Therapeutics Ltd. (NRSN) filed an S-8 registering securities for an employee benefit plan and incorporated prior public filings and its Form 8-A description. The filing outlines the companys indemnification and insurance framework for officers and directors, specifying circumstances where indemnity and insurance are permitted and where they are excluded, and includes undertakings to update the registration statement with required prospectus information, material changes to distribution plans, and to remove unsold securities at offering termination.
NeuroSense Therapeutics amended its prospectus supplement to update the maximum amount of ordinary shares it may sell through a Capital on Demand™ Sales Agreement with JonesTrading. The company may offer and sell ordinary shares having an aggregate offering price of up to $14,203,914, which does not include approximately $2.8 million of shares previously sold under the same agreement. Sales may be made as at-the-market offerings under Rule 415, and JonesTrading will act as sales agent but is not required to sell any specific number of shares.
The filing notes a Public Float of $50,961,630, based on 20,466,518 ordinary shares held by non-affiliates and a closing price of $2.49 used for that calculation. Because the Public Float is under $75.0 million, the company is limited by Form F-3 General Instruction I.B.5 to selling no more than one-third of that value in any 12-month period; during the last 12 months it sold about $2.8 million under this rule. The document reiterates that investing involves a high degree of risk and refers investors to the Risk Factors in the prospectus materials.
NeuroSense Therapeutics Ltd. (NRSN) filed a Form 6-K detailing the outcome of its pre-New Drug Submission (pre-NDS) meeting with Health Canada concerning PrimeC, the company’s investigational therapy for amyotrophic lateral sclerosis (ALS). The regulator discussed use of the Notice of Compliance with Conditions (NOC/c) expedited pathway, which could shorten the review timeline if eligibility is granted.
The parties are finalizing official minutes; a formal notice will confirm whether NeuroSense can proceed with an NDS under the NOC/c route. Management described the dialogue as constructive and positive but disclosed no definitive decision, review timetable, or financial metrics.
A comprehensive forward-looking statements section highlights risks including potential rejection or delay by Health Canada, funding requirements, Phase 3 timing, market-size uncertainties, and the company’s ability to remain listed on Nasdaq. No earnings data or new operational figures were provided.